Journal of Ningen Dock and Preventive Medical Care · Nov 12, 2026

FRAX-estimated Fracture Probability in Locomo Kenshin Examinees: Cross-sectional Associations with Multisite DXA Measures and GLFS-25

By Yoda T, Sogawa K, Yamamoto N et al.

Objective: To examine whether Fracture Risk Assessment Tool (FRAX)-estimated 10-year fracture probabilities derived from femoral neck bone mineral density (BMD) are associated with multisite BMD, locomotive function, muscle mass, and lifestyle factors in Locomo Kenshin (Ningen Dock) examinees.Methods: This cross-sectional study included 68 participants. Dual-energy X-ray absorptiometry was used to measure the BMD at the femoral neck, lumbar spine (L2–L4), and distal radius and calculate the appendicular skeletal muscle mass index (ASMI). Locomotive function was assessed using the 25-question Geriatric Locomotive Function Scale (GLFS-25) and locomotive syndrome (LS) grades. FRAX Major and FRAX Hip were calculated using the Japanese FRAX model with femoral neck BMD. Spearman correlation was used to assess the association between FRAX probabilities and non-femoral T-scores. Multiple linear regression was used to evaluate FRAX Major with GLFS-25 and ASMI after adjusting for age, sex, and body mass index. Exercise and calcium-containing food intake were included in the sensitivity analyses. An adjusted linear model was used to test the LS grade (categorical) and FRAX Major.Results: FRAX probabilities were inversely correlated with non-femoral T-scores. Age was associated with FRAX Major; by contrast, GLFS-25 and ASMI showed no independent association. Calcium-containing food intake was inversely associated with FRAX Major, whereas exercise was not. LS grade was not associated with FRAX Major after adjustment.Conclusions: The FRAX estimates aligned modestly with lumbar spine and distal radius BMD but had limited association with locomotive dysfunction or muscle mass, thus indicating the importance of complementary roles for integrated screening.

doi.org/10.11320/jndpmc.jndpmc-2025-014Powered by J-STAGEBiomarkers